Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PX-866 + Vemurafenib in BRAF-mutant Cancer
NCT01616199Phase 2Terminated
- Sponsor
- Cascadian Therapeutics
- Start
- Aug 2012
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sonolisib in melanoma, solid tumor, sponsored by Cascadian Therapeutics. Started Aug 2012; status: terminated.
02
Drugs
sonolisib
03
Conditions
melanomasolid tumor
Beyond the preview
Go deeper on NCT01616199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01616199.